Literature DB >> 20704620

Total hip arthroplasty in patients with chronic autoimmune inflammatory arthroplasties.

Roland Weng Wah Chong1, Choon Seng Chong, Choon Hin Lai.   

Abstract

OBJECTIVE: Patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) often require total hip arthroplasties. We present a retrospective review of 32 total hip arthroplasties (THA) performed for patients with SLE, RA or AS from 2003 to 2008 in a tertiary hospital in Singapore.
MATERIALS AND METHODS: A total of 323 THAs performed between January 2003 to December 2008 were traced and cases of arthroplasties performed for such patients were isolated. Pre- and post-operative range of motion, Harris hip score, limb length discrepancies and complications were studied.
RESULTS: Twenty-six patients aged 24-66 years (mean 47 years) were reviewed, with two AS patients (7.7%), 16 RA patients (61.5%), seven SLE patients (26.9%) and one patient (3.8%) with both RA and SLE. Thirty-two THA operations were conducted with six patients requiring bilateral THAs. The average follow-up was 3.3 years. Mean Harris hip score for 25 patients (one excluded due to patient expiry 2 month post-surgery) improved from 41.3 to 86.53 (P < 0.05). Mean pre-operative hip flexion improved from 61.3 degrees (0-120) to 89.7 degrees (30-120) (P < 0.05). Seventeen cases had preoperative limb length discrepancies (median 1 cm) which were all corrected. There were no implants loosening, infective arthritis, dislocations or neurovascular injuries documented.
CONCLUSION: Our series demonstrated the excellent outcome of THA for patients with chronic autoimmune arthropathies at the time of follow-up. Careful patient selection remains a priority as long-term outcomes for such patients of a significantly younger population is yet to be determined.

Entities:  

Mesh:

Year:  2010        PMID: 20704620     DOI: 10.1111/j.1756-185X.2010.01477.x

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  7 in total

1.  Total hip arthroplasty for vascular necrosis of the femoral head in patients with systemic lupus erythematosus: a midterm follow-up study of 28 hips in 24 patients.

Authors:  Yan Kang; Zi-ji Zhang; Xiao-yi Zhao; Zhi-qi Zhang; Pu-yi Sheng; Wei-ming Liao
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-02-05

2.  Bilaterally Primary Cementless Total Hip Arthroplasty for Severe Hip Ankylosis with Ankylosing Spondylitis.

Authors:  Dong-Xu Feng; Kun Zhang; Yu-Min Zhang; Yue-Wen Nian; Jun Zhang; Xiao-Min Kang; Shu-Fang Wu; Yang-Jun Zhu
Journal:  Orthop Surg       Date:  2016-08       Impact factor: 2.071

3.  Does Chronic Corticosteroid Use Increase Risks of Readmission, Thromboembolism, and Revision After THA?

Authors:  Matthew R Boylan; Dean C Perfetti; Randa K Elmallah; Viktor E Krebs; Carl B Paulino; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2015-11-09       Impact factor: 4.176

4.  A Comprehensive Assessment of Hip Damage in Ankylosing Spondylitis, Especially Early Features.

Authors:  Qing Han; Zhaohui Zheng; Kui Zhang; Jin Ding; Xenofon Baraliakos; Ping Zhu
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

5.  Reliability of Modified Harris Hip Score as a tool for outcome evaluation of Total Hip Replacements in Indian population.

Authors:  Prasoon Kumar; Ramesh Sen; Sameer Aggarwal; Saurabh Agarwal; Rajesh Kumar Rajnish
Journal:  J Clin Orthop Trauma       Date:  2017-12-06

6.  Outcome of total hip arthroplasty in patients with failed open reduction and internal fixation of acetabular fractures.

Authors:  Dharmendra Kumar; Shailendra Singh; Shubham Srivastava; Shitanshu Kumar Singh; Amit Singh; Yashvardhan Sharma
Journal:  J Clin Orthop Trauma       Date:  2021-06-19

7.  Quality of life following total hip arthroplasty in patients with acetabular fractures, previously managed by open reduction and internal fixation.

Authors:  Prasoon Kumar; Ramesh-Kumar Sen; Vishal Kumar; Ankit Dadra
Journal:  Chin J Traumatol       Date:  2016-08-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.